Lineage Cell Therapeutics CFO Jill Ann Howe acquires $17,100 in common shares
LCTX•Chief Financial Officer Jill Ann Howe purchased 20,000 Lineage Cell Therapeutics common shares at $0.855 each, raising her direct beneficial ownership to 45,500 shares.




